Travere Therapeutics names Bradley Campbell CEO effective Dec. 1
Travere Therapeutics appointed Bradley Campbell as president and chief executive officer, effective Dec. 1, as Eric Dube steps down to focus on health and family.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results.
Travere Therapeutics names Bradley L. Campbell as CEO
Travere Therapeutics appointed Bradley L. Campbell as President and Chief Executive Officer and board member effective December 1, 2026. Eric Dube will step down from those roles and become Executive Advisor and consultant.
Travere Therapeutics names Bradley Campbell CEO effective Dec. 1, 2026
Bradley L. Campbell appointed president and CEO of Travere Therapeutics, effective Dec. 1, 2026. Outgoing CEO Eric Dube to remain until that date and then serve as executive advisor through Feb. 15, 2027.